December 22, 2019
$76,055 Dr. Segal has significant experience in synthesizing molecules that bind to DNA and are able to regulate gene activity. ASF has provided funds to this investigator to pursue the possibilities that such agents, called artificial transcription factors, could have […]
Read more
December 21, 2019
$200,000 – 2-years This grant represents a continuation of funding for this investigator’s laboratory which was instrumental in identifying that a class of topoisomerase inhibitors can unsilence the paternal UBE3A gene. The investigator now plans to extend this work by […]
Read more
December 14, 2019
Summary of Dr. Gray study Dr. Steven Gray is applying his years of experience using gene therapy as a treatment for Giant Axonal Neuropathy (GAN), Rett syndrome, and several other neurological disorders to Angelman syndrome. Dr. Gray has been a […]
Read more
December 14, 2019
Summary of Dr. Philpot Study Dr. Ben Philpot is examining three new potential drugs for their ability to unsilence the paternal copy of Ube3a. These drugs were identified using the same approach Dr. Philpot previously used to identify topoisomerase inhibitors […]
Read more
December 14, 2019
Summary of Dr. Carney Study A national figure in cannabidiol (CBD) research, Dr. Paul Carney has been working with the National Academy of Medicine, the National Institute of Drug Abuse and the Florida Department of Health for several years to […]
Read more